普洛藥業(000739.SZ):琥珀酸地文拉法辛原料藥獲批上市
格隆匯6月5日丨普洛藥業(000739.SZ)公佈,近日,普洛藥業股份有限公司全資子公司浙江普洛家園藥業有限公司(簡稱“家園藥業”)收到國家藥品監督管理局簽發的琥珀酸地文拉法辛《化學原料藥上市申請批準通知書》。
琥珀酸地文拉法辛是第三代抗抑鬱藥,其通過抑制5-羥色胺-去甲腎上腺素再攝取機制來增加5-羥色胺和去甲腎上腺素濃度而發揮雙重抗抑鬱作用。該產品用於成人抑鬱症(MDD)的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.